JP2018008949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018008949A5 JP2018008949A5 JP2017130334A JP2017130334A JP2018008949A5 JP 2018008949 A5 JP2018008949 A5 JP 2018008949A5 JP 2017130334 A JP2017130334 A JP 2017130334A JP 2017130334 A JP2017130334 A JP 2017130334A JP 2018008949 A5 JP2018008949 A5 JP 2018008949A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- cdr
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102100033942 Ephrin-A4 Human genes 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 101100171806 Homo sapiens EFNA4 gene Proteins 0.000 claims description 6
- 108010043938 Ephrin-A4 Proteins 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 14
- 230000001613 neoplastic effect Effects 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 25
- 102000012803 ephrin Human genes 0.000 description 16
- 108060002566 ephrin Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 102000050554 Eph Family Receptors Human genes 0.000 description 7
- 108091008815 Eph receptors Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000020086 Ephrin-A1 Human genes 0.000 description 4
- 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000015861 cell surface binding Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 231100001221 nontumorigenic Toxicity 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108010043945 Ephrin-A1 Proteins 0.000 description 3
- 101000965523 Homo sapiens Ephrin-A1 Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 102000046760 human EFNA1 Human genes 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102000000075 EphB2 Receptor Human genes 0.000 description 1
- 108010055325 EphB3 Receptor Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 102000030797 EphB4 Receptor Human genes 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- 102100033940 Ephrin-A3 Human genes 0.000 description 1
- 108010043940 Ephrin-A3 Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42115710P | 2010-12-08 | 2010-12-08 | |
| US61/421,157 | 2010-12-08 | ||
| PCT/US2011/050451 WO2012031280A2 (en) | 2010-09-03 | 2011-09-02 | Identification and enrichment of cell subpopulations |
| USPCT/US2011/050451 | 2011-09-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Division JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018008949A JP2018008949A (ja) | 2018-01-18 |
| JP2018008949A5 true JP2018008949A5 (enExample) | 2018-06-14 |
| JP6491701B2 JP6491701B2 (ja) | 2019-04-03 |
Family
ID=46207727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Expired - Fee Related JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
| JP2017130334A Expired - Fee Related JP6491701B2 (ja) | 2010-12-08 | 2017-07-03 | 新規モジュレーターと使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Expired - Fee Related JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9320812B2 (enExample) |
| EP (2) | EP2648749A2 (enExample) |
| JP (2) | JP6279903B2 (enExample) |
| KR (1) | KR20140031175A (enExample) |
| CN (2) | CN106279415A (enExample) |
| AR (1) | AR084208A1 (enExample) |
| AU (4) | AU2011360938B2 (enExample) |
| BR (2) | BR112013014321A2 (enExample) |
| CA (2) | CA2820885A1 (enExample) |
| CO (1) | CO6821883A2 (enExample) |
| MX (1) | MX356400B (enExample) |
| NZ (3) | NZ705008A (enExample) |
| PE (2) | PE20171143A1 (enExample) |
| PH (2) | PH12013501137A1 (enExample) |
| RU (2) | RU2592672C9 (enExample) |
| SG (3) | SG191081A1 (enExample) |
| TW (2) | TWI585106B (enExample) |
| WO (2) | WO2012118547A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2592672C9 (ru) | 2010-12-08 | 2016-11-27 | СтемСентРкс, Инк. | Новые модуляторы и способы их применения |
| JP6454547B2 (ja) | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
| AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| CA2900764A1 (en) * | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
| US9765116B2 (en) * | 2013-04-18 | 2017-09-19 | Carmel Haifa University Economic Corporation Ltd. | Inhibitors of the Eph-A receptor and uses thereof |
| US10364288B2 (en) | 2013-05-24 | 2019-07-30 | Biogen Ma Inc. | Anti-GPIIB/IIIA antibodies or uses thereof |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3065780A1 (en) * | 2013-11-04 | 2016-09-14 | Pfizer Inc. | Anti-efna4 antibody-drug conjugates |
| US10538591B2 (en) * | 2014-03-10 | 2020-01-21 | The Brigham And Women's Hospital, Inc. | Anti-fibulin-3 antibodies and uses thereof |
| CN105504049B (zh) * | 2014-09-26 | 2019-07-05 | 艾托金生物医药（苏州）有限公司 | 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用 |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| CA2929542A1 (en) * | 2015-05-13 | 2016-11-13 | Pfizer Inc. | Treatment with anti-efna4 antibody-drug conjugates |
| MX2018009085A (es) * | 2016-01-27 | 2019-05-09 | Sutro Biopharma Inc | Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74. |
| EP3423495B1 (en) | 2016-03-01 | 2021-10-20 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
| SG11201806992VA (en) | 2016-03-04 | 2018-09-27 | Jn Biosciences Llc | Antibodies to tigit |
| CN109453382A (zh) * | 2018-11-08 | 2019-03-12 | 浙江大学 | EphrinA1蛋白在制备用于抑制肿瘤细胞侵袭、转移的药物中的应用 |
| CN113573728A (zh) * | 2018-11-14 | 2021-10-29 | 安驰肿瘤公司 | 治疗性SIRPα抗体 |
| KR20220034733A (ko) * | 2019-05-27 | 2022-03-18 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 타우의 입체형태-특이적 에피토프, 이에 대한 항체 및 이와 관련된 방법 |
| CN115698068A (zh) | 2020-06-02 | 2023-02-03 | 艾库斯生物科学有限公司 | 抗tigit抗体 |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
| KR20230142330A (ko) | 2022-03-31 | 2023-10-11 | 주식회사 에스알이엔지 | 일체형 수배전반 열화 방지 시스템 및 이를 이용한 열화 방지 방법 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE145428T1 (de) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| WO1994004670A1 (en) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| CN1117155C (zh) | 1994-07-29 | 2003-08-06 | 史密丝克莱恩比彻姆有限公司 | 新型化合物 |
| US5919905A (en) * | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| KR20030096450A (ko) | 1996-03-22 | 2003-12-31 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사 유도 분자 ⅱ |
| WO1998001548A1 (en) | 1996-07-05 | 1998-01-15 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| DE69839060T2 (de) | 1997-11-03 | 2009-01-15 | Human Genome Sciences, Inc. | Vegi, ein inhibitor der angiogenese und des tumorwachstums |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| AU6902200A (en) | 1999-08-11 | 2001-03-05 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6992170B2 (en) * | 1999-10-15 | 2006-01-31 | Curagen Corporation | Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| AU1574401A (en) | 1999-10-20 | 2001-04-30 | Zymogenetics Inc. | Granulocyte peptide homolog zgpa1 |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US20040043928A1 (en) | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2003064589A2 (en) | 2001-01-23 | 2003-08-07 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| CA2452578A1 (en) | 2001-07-03 | 2003-01-16 | The Hospital For Sick Children | Ephrin and eph receptor mediated immune modulation |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| CA2466333A1 (en) | 2001-11-09 | 2003-05-15 | Neuronova Ab | Method of proliferation in neurogenic regions |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| WO2003075957A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| AU2003276832A1 (en) | 2002-05-10 | 2004-02-25 | Medimmune, Llc | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
| EP1852441B1 (en) | 2002-09-24 | 2012-03-28 | The Burnham Institute | Agents that modulate EPH receptor activity |
| CA2499580A1 (en) | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| DK2364996T3 (en) | 2002-09-27 | 2017-02-06 | Xencor Inc | Optimized Fc variants and methods for their formation |
| AU2003272799A1 (en) | 2002-09-27 | 2004-04-19 | Incyte Corporation | Receptors and membrane-associated proteins |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| KR20060034231A (ko) * | 2003-06-06 | 2006-04-21 | 메디뮨 인코포레이티드 | 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 |
| US20050153923A1 (en) | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| CA2577329A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| WO2006047298A2 (en) | 2004-10-21 | 2006-05-04 | The Penn State Research Foundation | Eph receptor tumor biomarkers |
| WO2006052409A2 (en) | 2004-10-23 | 2006-05-18 | Case Western Reserve University | Peptide and small molecule agonists of epha and their uses |
| EP1809326A4 (en) | 2004-10-27 | 2009-11-04 | Medimmune Inc | MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN |
| JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン，エルエルシー | 毒素とコンジュゲートしたｅｐｈ受容体抗体 |
| US7807459B2 (en) | 2005-09-27 | 2010-10-05 | Reneuron, Inc. | EphA4-positive human adult pancreatic endocrine progenitor cells |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| EP2004228A1 (en) | 2006-02-28 | 2008-12-24 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-epha4 antibodies |
| JP5167155B2 (ja) | 2006-03-09 | 2013-03-21 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 |
| US20080003210A1 (en) | 2006-03-13 | 2008-01-03 | Medimmune, Inc. | Non-human primate receptor tyrosine kinases |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| CA2658003A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| NZ596865A (en) * | 2006-06-12 | 2013-07-26 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
| NZ574215A (en) * | 2006-07-18 | 2012-07-27 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| AU2007291891B2 (en) * | 2006-08-31 | 2013-10-31 | A.C.N. 135 493 391 Pty Ltd | Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions |
| PL2063907T3 (pl) | 2006-09-07 | 2018-06-29 | Frankel | Sposoby i kompozycje oparte na koniugatach toksyny błoniczej z interleukiną-3 |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| DK3199180T3 (da) * | 2007-03-08 | 2022-03-21 | Humanigen Inc | Epha3-antistoffer til behandlingen af faste tumorer |
| EP2676678A1 (en) | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| AU2008296386A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| WO2009039192A2 (en) * | 2007-09-17 | 2009-03-26 | The Regents Of The University Of Californina | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| EP2205277B1 (en) * | 2007-10-22 | 2017-07-26 | Genmab A/S | Novel antibody therapies |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010066835A2 (en) | 2008-12-10 | 2010-06-17 | Ablynx Nv | Eph receptor and ephrin ligand interaction |
| KR20110108390A (ko) | 2009-01-12 | 2011-10-05 | 신텔렉트 인코포레이티드 | 레이저로 매개된 박막 절개 및 세포 군체의 이동 |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| EP2446895A1 (en) | 2010-10-01 | 2012-05-02 | Stemgen S.P.A. | EPH receptor expression in tumor stem cells |
| RU2592672C9 (ru) | 2010-12-08 | 2016-11-27 | СтемСентРкс, Инк. | Новые модуляторы и способы их применения |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-12-07 RU RU2013128444/10A patent/RU2592672C9/ru not_active IP Right Cessation
- 2011-12-07 PE PE2017000463A patent/PE20171143A1/es unknown
- 2011-12-07 EP EP11802250.8A patent/EP2648749A2/en not_active Withdrawn
- 2011-12-07 PH PH1/2013/501137A patent/PH12013501137A1/en unknown
- 2011-12-07 CA CA2820885A patent/CA2820885A1/en not_active Abandoned
- 2011-12-07 WO PCT/US2011/063831 patent/WO2012118547A1/en not_active Ceased
- 2011-12-07 BR BR112013014321-5A patent/BR112013014321A2/pt not_active IP Right Cessation
- 2011-12-07 TW TW100145222A patent/TWI585106B/zh not_active IP Right Cessation
- 2011-12-07 SG SG2013044417A patent/SG191081A1/en unknown
- 2011-12-07 EP EP11801934.8A patent/EP2648748A1/en not_active Withdrawn
- 2011-12-07 AU AU2011360938A patent/AU2011360938B2/en not_active Ceased
- 2011-12-07 RU RU2016123839A patent/RU2016123839A/ru not_active Application Discontinuation
- 2011-12-07 CA CA2819861A patent/CA2819861A1/en not_active Abandoned
- 2011-12-07 MX MX2013006569A patent/MX356400B/es active IP Right Grant
- 2011-12-07 BR BR112013014119A patent/BR112013014119A8/pt not_active Application Discontinuation
- 2011-12-07 CN CN201610633887.7A patent/CN106279415A/zh active Pending
- 2011-12-07 NZ NZ705008A patent/NZ705008A/en not_active IP Right Cessation
- 2011-12-07 SG SG2013043039A patent/SG190990A1/en unknown
- 2011-12-07 SG SG10201601792UA patent/SG10201601792UA/en unknown
- 2011-12-07 AR ARP110104586A patent/AR084208A1/es unknown
- 2011-12-07 NZ NZ728016A patent/NZ728016A/en not_active IP Right Cessation
- 2011-12-07 US US13/992,599 patent/US9320812B2/en not_active Expired - Fee Related
- 2011-12-07 CN CN201180065609.1A patent/CN103347538B/zh not_active Expired - Fee Related
- 2011-12-07 KR KR1020137017734A patent/KR20140031175A/ko not_active Abandoned
- 2011-12-07 PE PE2013001372A patent/PE20140673A1/es active IP Right Grant
- 2011-12-07 US US13/995,086 patent/US20140302034A1/en not_active Abandoned
- 2011-12-07 WO PCT/US2011/063834 patent/WO2012078813A2/en not_active Ceased
- 2011-12-07 TW TW106101451A patent/TWI655210B/zh not_active IP Right Cessation
- 2011-12-07 NZ NZ611428A patent/NZ611428A/en not_active IP Right Cessation
- 2011-12-07 AU AU2011338425A patent/AU2011338425A1/en not_active Abandoned
- 2011-12-07 JP JP2013543326A patent/JP6279903B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-07 CO CO13138765A patent/CO6821883A2/es active IP Right Grant
-
2016
- 2016-03-17 US US15/072,811 patent/US9969798B2/en not_active Expired - Fee Related
- 2016-03-17 US US15/072,930 patent/US9765136B2/en not_active Expired - Fee Related
- 2016-10-19 AU AU2016247113A patent/AU2016247113A1/en not_active Abandoned
-
2017
- 2017-06-16 PH PH12017501139A patent/PH12017501139A1/en unknown
- 2017-07-03 JP JP2017130334A patent/JP6491701B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-18 US US15/956,213 patent/US20180237512A1/en not_active Abandoned
- 2018-10-18 AU AU2018250466A patent/AU2018250466A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018008949A5 (enExample) | ||
| US11220551B2 (en) | CD133-binding agents and uses thereof | |
| US9975954B2 (en) | Anti-Axl antibodies | |
| JP2017535257A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| Jain et al. | The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine | |
| JP2019500020A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2013544493A5 (enExample) | ||
| WO2015193430A1 (en) | Anti-axl antibodies | |
| JP2011505146A5 (enExample) | ||
| RU2013128444A (ru) | Новые модуляторы и способы их применения | |
| CN115052896A (zh) | 抗ror1抗体和组合物 | |
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| Dengl et al. | Engineered hapten‐binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery | |
| JP2014515600A5 (enExample) | ||
| KR20180054492A (ko) | CD66c에 특이적으로 결합하는 항체 및 그의 용도 | |
| JP2018528759A5 (enExample) | ||
| AU2017352553A1 (en) | Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use | |
| JP2023103439A (ja) | 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| JPWO2019212965A5 (enExample) | ||
| Zhou et al. | Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2 | |
| WO2020247827A1 (en) | Antigen-binding protein constructs and uses thereof | |
| KR20210031913A (ko) | 항-인간 pd-l1 항체 및 그것의 용도 | |
| JP7604452B2 (ja) | 結合メンバー |